Latest Orthopaedics News

Page 1 of 6
Desane Group Holdings (ASX:DGH) is entering FY27 with a $105.9 million asset base, conservative gearing and two developments expected to drive its next phase of earnings. The challenge is converting that balance-sheet strength into recurring income while navigating construction costs, funding risk and a chairman transition.
Eva Park
Eva Park
5 Nov 2026
Zimmer Biomet lifted its full-year 2026 sales and adjusted earnings guidance after third-quarter constant-currency growth accelerated to 3.7%. The result was supported by strong hips, sports medicine and technology sales, although GAAP earnings fell and knees remained a weak spot.
Ada Torres
Ada Torres
4 Nov 2026
Marine Biomedical has secured US FDA 510(k) clearance for PearlBone, giving Orthocell a clearer path into bone regeneration through its 12% strategic stake and distribution rights. The commercial opportunity is advancing, but revenue, launch timing and definitive distribution arrangements remain undisclosed.
Ada Torres
Ada Torres
3 Nov 2026
Osteopore reported record quarterly revenue of A$859,000 in Q3 CY26 as it added market access in Thailand and Saudi Arabia and completed its first customised Hainan implant. The regenerative implant maker remains cash-flow negative, with A$712,000 in cash and A$14 million still available under its convertible note facility.
Victor Sage
Victor Sage
30 Oct 2026
Saluda Medical delivered a strong operational start to FY27, with US implants up 55% and quarterly revenue rising 26% to US$23.1 million. But the medical device company ended September with US$73.6 million in cash, US$100 million of secured debt drawn and estimated funding for just 2.3 quarters at the quarter’s cash-use rate.
Ada Torres
Ada Torres
29 Oct 2026
Saluda Medical delivered 28% FY26 revenue growth and expanded its spinal cord stimulation opportunity with CAP24, but its annual report warns that additional capital may be needed within 12 months. The ASX-listed medical device company also begins FY27 under new CEO Michael Mathias.
Victor Sage
Victor Sage
23 Oct 2026
Orthocell’s flagship Remplir nerve-repair product gained ground in the US and Thailand during the September quarter, even as total revenue slipped from the June period. The company reported A$39 million in available funds and said it does not currently expect to raise additional capital.
Ada Torres
Ada Torres
22 Oct 2026
CurveBeam AI has secured its strongest first-quarter HiRise sales result, gained China regulatory clearance and raised A$7.35 million to fund the next stage of commercialisation. The progress comes alongside lower customer receipts and a reported 4.3 quarters of cash runway.
Victor Sage
Victor Sage
21 Oct 2026
Orthocell has recorded the first commercial sales of its Remplir nerve repair product in Thailand, opening a new market estimated at US$84 million. The launch gives the company another distributor-led growth channel, although near-term sales are expected to remain modest.
Ada Torres
Ada Torres
21 Sept 2026
CurveBeam AI has secured FDA 510(k) clearance for CT-based bone mineral density measurement, establishing the first regulatory step towards a potential new SaaS offering. The more commercially significant HiRise weight-bearing application still requires a separate clearance.
Victor Sage
Victor Sage
15 Sept 2026
CurveBeam AI has secured over A$600,000 through its Share Purchase Plan, bolstering funds alongside a recent A$5 million placement. The capital will fuel the China launch and product development for its HiRise™ CT scanner.
Ada Torres
Ada Torres
1 Sept 2026
Ramsay Health Care has finalised its $251 million purchase of National Capital Private Hospital in Canberra, expanding its footprint in key therapeutic areas and expecting earnings accretion within a year.
Ada Torres
Ada Torres
1 Sept 2026

Browse the archive

Full archive